Samchundang Pharm announced on the 19th that it has submitted a Clinical Trial Application (CTA) to the European Medicines Agency (EMEA) for its oral insulin candidate.



The purpose of the clinical trial is to evaluate and compare the pharmacokinetic and pharmacodynamic properties of the oral insulin candidate (SCD0503) with those of subcutaneous insulin under normal glucose clamp conditions in patients with type 1 diabetes. The clinical trial period is expected to be within approximately nine months from the date of approval.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing